Bectumomab

N/A

Report date: 2025/11/18 17:45:21

Base Information

Drug NameBectumomab

Drug Alias NameImmuRAID LL2 Tc 99mAnti-CD22 monoclonal antibody LL2 Tc 99mLymphoScan

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive diagnostic agent +[6]

Mechanisms of ActionRadionuclide imaging enhancers

TargetsCD22

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunomedics Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A